Trial Profile
An open-label, dose-escalating clinical Phase 1/2a trial evaluating the safety, pharmacokinetics (PK), and antitumor activity of modified allogeneic C.I.K. cells administered to pediatric and adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs CMN 005 (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 13 Dec 2022 Results presented in a CoImmune Media Release.
- 15 Dec 2021 Results presented in a CoImmune Media Release.
- 15 Dec 2021 According to a CoImmune media release, data presented at 63rd ASH Annual Meeting & Exposition.